Boston Scientific

BSX

Market cap $71.8B

Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.

Just after that, several analysts published new, bearish takes on the stock. One felt compelled to downgrade his recommendation on the medical device giant.

Boston Scientific (BSX) concluded the recent trading session at $49.11, signifying a -2.68% move from its prior day's close.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device ​maker flagged declining usage of its heart disease device.

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election as a director of Belo Sun at the Company's Annual and Special Meeting of Shareholders held on May 26, 2026 (the “Meeting”), was elected.

WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?